1.
Gynecol Oncol Rep
; 26: 91-93, 2018 Nov.
Artículo
en Inglés
| MEDLINE
| ID: mdl-30426062
RESUMEN
A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialysis and a clinically significant disease response was appreciated.